X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering are expected to be approximately $135 million before deducting underwriting discounts and commissions and other offering expenses payable by X4, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 27, 2025, subject to the satisfaction of customary closing conditions. In addition, X4 has granted the underwriters an option for a period of 30 days to purchase up to an additional 6,984,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by X4.

Read more at globenewswire.com